Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Nivolumab +/- Radiotherapy in Melanoma Brain Metastases
NCT03340129Phase 2Recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Aug 2019
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in melanoma, sponsored by Melanoma Institute Australia. Started Aug 2019; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03340129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340129.